Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 3, 2017, Pages 906-913

  Palacios Baena, Zaira Raquel ^a   Gutierrez Gutierrez, Belen ^a   De Cueto, Marina ^a,b   Viale, Pierluigi ^c   Venditti, Mario ^d   Hernández Torres, Alicia ^e   Oliver, Antonio ^f   Martínez Martínez, Luis ^g   Calbo, Esther ^h   Pintado, Vicente ⁱ   Gasch, Oriol ^j   Almirante, Benito ^k   Antonio Lepe, José ^a   Pitout, Johann ^l   Akova, Murat ^m   Peña Miralles, Carmen ⁿ   Schwaber, Mitchell J ^o   Tumbarello, Mario ^p   Tacconelli, Evelina ^q   Origüen, Julia ^r   Prim, Nuria ^s   Bou, German ^t   Giamarellou, Helen ^u   Bermejo, Joaquín ^v   Hamprecht, Axel ^w   Pérez, Federico ^x   Almela, Manuel ^y   Lowman, Warren ^z   Hsueh, Po Ren ^aa   Navarro San Francisco, Carolina ^ab   Torre Cisneros, Julián ^ac   Carmeli, Yehuda ^o   Bonomo, Robert A ^ad   Paterson, David L ^ae   Pascual, Alvaro ^a,b   Rodriguez Bano, Jesus ^a,b   more..

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h HOSPITAL MÚTUA DE TERRASSA   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j Parc Tauli Health Corporation   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l UNIVERSITY OF CALGARY   (Canada)

^m HACETTEPE UNIVERSITY   (Turkey)

ⁿ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^o TEL AVIV UNIVERSITY   (Israel)

^p CATHOLIC UNIVERSITY   (Italy)

^q UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^r HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^s HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^t HOSPITAL JUAN CANALEJO   (Spain)

^u IASO GENERAL HOSPITAL   (Greece)

^v HOSPITAL ESPAÑOL   (Argentina)

^w UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^x CASE WESTERN RESERVE UNIVERSITY   (United States)

^y HOSPITAL CLÍNIC   (Spain)

^z University of the Witwatersrand   (South Africa)

^aa NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^ab HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^ac HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^ad CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ae UNIVERSITY OF QUEENSLAND   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE;

AGED; BACTEREMIA; BIOSYNTHESIS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; FEMALE; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA; KLEBSIELLA INFECTIONS; MALE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; SEPSIS; STATISTICAL MODEL; VALIDATION STUDY;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; KLEBSIELLA; KLEBSIELLA INFECTIONS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SEPSIS;

EID: 85031037345     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw513     Document Type: Article

References (24)

1. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2014. Antimicrobial Resistance and Healthcare-associated Infections. Stockholm: ECDC; 2015. http://ecdc.europa.eu/en/publications/publications/ antimicrobial-resistance-annual-epidemiological-report.pdf.
2. Rodriguez-Bano J, Pascual A. Clinical significance of extended spectrum blactamases. Expert Rev Anti Infect Ther 2008; 6: 671-83.
3. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum b-lactamase-producing Enterobacteriaceae and patient outcome: a metaanalysis. JAntimicrobChemother 2012; 67: 1311-20.
4. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum b-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. JAntimicrobChemother 2007; 60: 913-20.
5. Taconelli E, CataldoMA, De Angelis G et al. Risk scoring and bloodstream infections. Int J Antimicrob Agents 2007; 30: S88-92.
6. TumbarelloM, Trecarichi EM, BassettiMet al. Identifying patients harbouring ESBL-producing Enterobacteriaceae on hospital admission. Antimicrob Agents Chemother 2011; 55: 3485-90.
7. Johnson SW, Anderson DJ, Byron May D et al. Utility of a clinical risk factor scoringmodel in predicting infection with extended-spectrum-b-lactamaseproducing Enterobacteriaceae on hospital admission. Infect Control Hosp Epidemiol 2013; 34: 385-92.
8. Al-Hasan MN, Lahr BD, Eckel-Passow JE et al. Predictive scoring model of mortality in Gram-negative bloodstream infection. Clin Microbiol Infect 2013; 19: 948-54.
9. Al-Hasan MN, Juhn YJ, Bang DW et al. External validation of bloodstream infection mortality risk score in a population-based cohort. Clin Microbiol Infect 2014; 20: 886-91.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational SupplementM100-S22. CLSI,Wayne, PA, USA, 2012.
11. McCabe WR, Jackson GG. Gram-negative bacteremia: II. Clinical, laboratory, and therapeutic observations. Arch Intern Med 1962; 110: 856-64.
12. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. JChronicDis 1987; 40: 373-83.
13. Hilf M, Yu V, Sharp J et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am JMed1989; 87: 540-6.
14. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.AmJ Infect Control 2008; 36: 309-32.
15. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit CareMed 1992; 20: 864-74.
16. Bai AD, Showler A, Burry L et al. Clinical prediction rules in Staphylococcus aureus bacteremia demonstrate the usefulness of reporting likelihood ratios in infectious diseases. Eur J ClinMicrobiol Infect Dis 2016; 35: 1393-8.
17. Kang CI, KimSH, ParkWB et al. Bloodstreaminfections due to extendedspectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574-81.
18. Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patientswith bloodstream infections caused by extended-spectrum-b-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51: 1987-94.
19. Frakking FN, Rottier WC, Dorigo-Zetsma JW et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extendedspectrum-b-lactamase-producing bacteria. Antimicrob Agents Chemother 2013; 57: 3092-9.
20. Rodriguez-Bano J, Picon E, Gijon P et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-b-lactamase-producing Escherichia coli. JClinMicrobiol 2010; 48: 1726-31.
21. Minton J, Clayton J, Sandoe J et al. Improving early management of bloodstream infection: a quality improvement project.BMJ 2008; 336: 440-3.
22. Rodriguez-Bano J, de Cueto M, Retamar P et al. Current management of bloodstream infections. Expert Rev Anti Infect Ther 2010; 8: 815-29.
23. Retamar P, Portillo M, Lopez-Prieto M et al. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 2012; 56: 472-8.
24. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M et al. A predictivemodel of mortality in patients with bloodstream infection due to carbapenemaseproducing Enterobacteriaceae. Mayo Clin Proc 2016; 91: 1362-71.